EICHOR ● Active Not Recruiting

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Condition: Metastatic Breast Cancer · Sponsor: AstraZeneca

PhasePhase 1

Planned participants138

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (37)

Research Site	Commack, New York, United States	—
Research Site	Harrison, New York, United States	—
Research Site	New York, New York, United States	—
Research Site	New York, New York, United States	—
Research Site	Uniondale, New York, United States	—
Research Site	Chapel Hill, North Carolina, United States	—
Research Site	Chattanooga, Tennessee, United States	—
Research Site	Germantown, Tennessee, United States	—
Research Site	Fort Worth, Texas, United States	—
Research Site	Melbourne, Australia	—
Research Site	Westmead, Australia	—
Research Site	Edegem, Belgium	—

+ 25 more locations — full list on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →